propofol-remifentanil

ApprovedSmall molecule

YYonsei University

propofol-remifentanil is one of 63 small molecule programs targeting Metastasis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetastasisActive, not recruiting

HypotensionActive, not recruiting

MetastasisPreclinical

Active, not recruiting

HypotensionPreclinical

Active, not recruiting

Competition

Competitive Landscape

159 competitors in Metastasis

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

4 2

Yervoy

Bristol-Myers Squibb

Phase 3

3 3

PEG-Intron

Intron a

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 6

Alimta

EEagle Vision Pharmaceutical Corp.

Phase 3

1 7

Herceptin

OOrganon and Co

Phase 3

1 8

Conmana

BBetta Pharmaceuticals Co., Ltd.

Phase 3

1 9

Vascepa

AAmarin Pharma Inc.

Phase 3

1 10

Lenvima

Eisai

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sedation1 trial

A Comparison of Surgical Outcome Following Drug-induced Sleep Endoscopic Diagnosis Using Propofol or Dexmedetomidine for Sedation : A Prospective Randomized Trial

Completed·YYonsei University·Phase 4·NCT01895348·60 enrolled

ALS1 trial

Detection of Consciousness by EEG and Auditory Evoked Potentials

Completed·TTechnical University of Munich·Phase 4·NCT01720615·80 enrolled

Intravenous Anesthesia1 trial

Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors

Withdrawn·TThe Cleveland Clinic·N/A·NCT00555984

Hypotension1 trial

Anesthesia Techniques, Neuroprotection and Surgical Field in FESS Under Controlled Hypotension

Recruiting·—·N/A·NCT07181564·150 enrolled

Metastasis1 trial

Comparison of the Effect of Total Intravenous Anesthesia and Inhalation Anesthesia on Cancer Cell Cytotoxicity, Micrometastasis and Recurrence of Tumor in Patients Undergoing Breast Tumor Resection

Terminated·YYonsei University·N/A·NCT02089178·48 enrolled

2 more indications

Pediatric Patients1 trial

Remifentanil and Laryngeal Reflex Responses in Pediatric Patients With URI

Completed·TThomas Erb·Phase 4·NCT00611195·62 enrolled

Hemostasis1 trial

Different Hemostasis According to the Anesthetic Agents

Completed·SSeoul National University Bundang Hospital·N/A·NCT02151305·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for propofol-remifentanil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — propofol-remifentanil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for propofol-remifentanil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: YYonsei University

propofol-remifentanil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sedation1 trial

ALS1 trial

Intravenous Anesthesia1 trial

Hypotension1 trial

Metastasis1 trial

Pediatric Patients1 trial

Hemostasis1 trial

References

Drug Info

Quick Facts

Related News